Association of the incidence of postherpetic neuralgia with early treatment intervention of herpes zoster and patient baseline characteristics: A systematic review and meta-analysis of cohort studies

被引:1
作者
Ding, Shaoli [1 ,2 ]
Wen, Shiqi [3 ]
Kang, Hongxia [2 ]
Zhang, Haijun [1 ,4 ]
Guo, Hong [1 ,5 ]
Li, Yulan [1 ,4 ]
机构
[1] Lanzhou Univ, Clin Med Sch 1, Lanzhou, Gansu, Peoples R China
[2] Gansu Prov Hosp, Dept Pain Management, Lanzhou, Gansu, Peoples R China
[3] Gansu Prov Hosp, Dept Vasc Surg, Lanzhou, Gansu, Peoples R China
[4] Lanzhou Univ, Hosp 1, Dept Anaesthesiol, Lanzhou, Gansu, Peoples R China
[5] Inner Mongolia Canc Hosp, Dept Anaesthesiol, Mongolia, Peoples R China
关键词
Herpes zoster; Neuralgia; Postherpetic; Risk factors; Meta-analysis; RISK-FACTORS; PAIN; QUALITY;
D O I
10.1016/j.ijid.2024.107181
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To conduct a meta-analysis of the association between postherpetic neuralgia (PHN), baseline characteristics of patients with herpes zoster (HZ), and early interventions. Methods: Literature searches were conducted in seven databases, in June 2021 and updated in June 2022. Two investigators independently conducted literature screening and data extraction, and the studies were evaluated according to the Newcastle-Ottawa scale. Results: A total of 53 cohort studies were included. The meta-analyses identified skin lesions, timing of initial treatment ( >= 3 days), and comorbidities as potential risk factors for PHN. In contrast, female sex (odds ratio [OR] = 1.13, 95% confidence interval [CI]: 0.99-1.29), cervical herpes (OR = 0.80, 95% CI: 0.212.99), lumbar herpes (OR = 1.29, 95% CI: 0.61-2.74), and immunosuppressive therapy (OR = 1.96, 95% CI: 0.22-17.12), were not significantly associated with PHN. In addition, glucocorticoid use (OR = 0.61, 95% CI: 0.22-1.70) may be a protective factor for the development of PHN; however, the difference was not statistically significant. Conclusion: A series of baseline characteristics were identified among populations at high risk of developing PHN from HZ. Additionally, the timing of initial treatment is associated with PHN occurrence. The preventive effect of glucocorticoids warrants further validation. (c) 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页数:8
相关论文
共 27 条
  • [1] Effectiveness of Intravenous Immunoglobulin for Management of Neuropathic Pain: A Narrative Review
    Chang, Min Cheol
    Park, Donghwi
    [J]. JOURNAL OF PAIN RESEARCH, 2020, 13 : 2879 - 2884
  • [2] Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific
    Chen, Liang-Kung
    Arai, Hidenori
    Chen, Liang-Yu
    Chou, Ming-Yueh
    Djauzi, Samsuridjal
    Dong, Birong
    Kojima, Taro
    Kwon, Ki Tae
    Leong, Hoe Nam
    Leung, Edward M. F.
    Liang, Chih-Kuang
    Liu, Xiaohong
    Mathai, Dilip
    Pan, Jiun Yit
    Peng, Li-Ning
    Poblete, Eduardo Rommel S.
    Poi, Philip J. H.
    Reid, Stewart
    Tantawichien, Terapong
    Won, Chang Won
    [J]. BMC INFECTIOUS DISEASES, 2017, 17
  • [3] Chen WK, 2019, Lab Med Clin, V16, P2995
  • [4] Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States
    Florea, Ana
    Sy, Lina
    Qian, Lei
    Ackerson, Bradley
    Luo, Yi
    Wu, Jun
    Cheng, Yanjun
    Ku, Jennifer
    Daily, Leticia Vega
    Takhar, Harpreet
    Song, Jeannie
    Chmielewski-Yee, Elizabeth
    Spence, O'Mareen
    Seifert, Harry
    Oraichi, Driss
    Tseng, Hung Fu
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [5] Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: A cohort study
    Forbes, Harriet J.
    Bhaskaran, Krishnan
    Thomas, Sara L.
    Smeeth, Liam
    Clayton, Tim
    Mansfield, Kathryn
    Minassian, Caroline
    Langan, Sinead M.
    [J]. NEUROLOGY, 2016, 87 (01) : 94 - 102
  • [6] A systematic review and meta-analysis of risk factors for postherpetic neuralgia
    Forbes, Harriet J.
    Thomas, Sara L.
    Smeeth, Liam
    Clayton, Tim
    Farmer, Ruth
    Bhaskaran, Krishnan
    Langan, Sinead M.
    [J]. PAIN, 2016, 157 (01) : 30 - 54
  • [7] Galluzzi KE, 2009, J AM OSTEOPATH ASSOC, V109, pS7
  • [8] Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom
    Gauthier, A.
    Breuer, J.
    Carrington, D.
    Martin, M.
    Remy, V.
    [J]. EPIDEMIOLOGY AND INFECTION, 2009, 137 (01) : 38 - 47
  • [9] Hope-Simpson R E, 1975, J R Coll Gen Pract, V25, P571
  • [10] Johnson Robert W, 2015, Ther Adv Vaccines, V3, P109, DOI 10.1177/2051013615599151